Leadership Team

Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015, and as interim Chair of the Board since November 2021. She has has led the company through its transition to the public market; the approval of PHEXXI^® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand prescription contraceptive vaginal gel; the acquisition of SOLOSEC® (secnidazole) 2 g oral granules, an oral antibiotic approved to treat bacterial vaginosis and trichomoniasis with just one dose; and four consecutive years of net sales growth.

Ivy Zhang is a trusted leader and seasoned finance executive with more than 14 years of financial and accounting experience spanning diverse industries, including pharmaceuticals and medical devices, who is dedicated to advancing Evofem Biosciences’ mission of addressing the unmet sexual and reproductive health needs of women. She joined Evofem as Chief Financial Officer and Secretary in April 2023 and leads the Company’s finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions.

Kathy joined Evofem in January 2021 as Vice President of Sales.  She has been responsible for effectively designing and executing sales force strategies to drive significant revenue growth and an optimal sales team.  She specializes in aligning sales initiatives with corporate goals and building and leading high-performing sales teams that succeed through a culture of inclusion, collaboration, and engagement.

Since joining Evofem in 2018, Amy has progressively advanced to senior leadership roles, culminating in her appointment as Chief Business Development Officer in 2024. In this capacity, she successfully established the company’s first ex-U.S. commercial agreement for Phexxi® (lactic acid, citric acid, and bitartrate), paving the way for the hormone-free contraceptive’s entry into the UAE and other GCC markets. Additionally, she spearheaded Evofem’s acquisition of SOLOSEC® (secnidazole) 2g granules, an FDA-approved single-dose oral antibiotic for two common sexual health conditions.

In addition, to-date Amy has successfully negotiated two ex-U.S. commercial agreements that expand and diversify Evofem’s revenue stream. Our licensee for the Middle East plans to launch Phexxi® (lactic acid, citric acid, and bitartrate) and SOLOSEC in the first quarter of 2026 in the United Arab Emirates, followed by additional markets in the licensed Territory.

Ellen Thomas, Evofem Biosciences’ Chief of Staff, has over 30 years of professional experience in board management and corporate governance, healthcare communications, global operations, marketing, thought leader engagement, global meeting/conference event management, pharmaceutical sales, continuing medical education and management consulting. She joined Evofem in January 2013 and has worked for Saundra Pelletier since July 2009.